M
Mu Li
Researcher at Xi'an Jiaotong University
Publications - 9
Citations - 283
Mu Li is an academic researcher from Xi'an Jiaotong University. The author has contributed to research in topics: Cell growth & HeLa. The author has an hindex of 7, co-authored 9 publications receiving 233 citations.
Papers
More filters
Journal ArticleDOI
miR-99a and -99b inhibit cervical cancer cell proliferation and invasion by targeting mTOR signaling pathway
TL;DR: Results suggested that miR-99a/b directly and negatively regulated mTOR expression in cervical cancer cells, and enforced the importance of miR/b and their targets in the malignant phenotypes of cervical carcinogenesis.
Journal ArticleDOI
EphB2 promotes cervical cancer progression by inducing epithelial-mesenchymal transition
TL;DR: Findings demonstrate that EphB2 plays an important role in cervical cancer progression by orchestrating an EMT program through R-Ras activation.
Journal ArticleDOI
The homologous recombination protein RAD51 is a promising therapeutic target for cervical carcinoma
TL;DR: It is demonstrated for the first time that inhibition of RAD51 suppressed the cervical cancer cell proliferation and the growth of cervical cancer xenografts by attenuating cell cycle transition, which could be a functional link between RAD51 and cyclin D1 and p21.
Journal ArticleDOI
Hiwi facilitates chemoresistance as a cancer stem cell marker in cervical cancer
TL;DR: Immunochemical analysis showed a significantly higher frequency of Hiwi staining in high-grade squamous intraepithelial lesions (HSILs) and cervical cancer tissues when comparing with the frequency in normal cervices, and results suggest that HiwI may participate in the carcinogenesis of cervical cancer and may be a potential therapeutic target molecule for cervical cancers.
Journal ArticleDOI
Oxymatrine induces apoptosis in human cervical cancer cells through guanine nucleotide depletion.
TL;DR: Results suggest that targeting of IMPDH2 by potential pharmacological inhibitors, oxymatrine in combination with chemotherapy, might be a promising means of overcoming chemoresistance in cervical cancer with high IM PDH2 expression, and may thus provide new insights into the mechanism of oxyamtrine-induced anticancer effects.